Glioblastoma is a highly aggressive form of brain cancer characterized by uncontrolled cell growth resulting from a loss of cell cycle regulation. In this study we determined the antiproliferative eects of interferon gamma (IFNg) on the glioblastoma cell lines T98G, SNB-19 and U-373, focusing on the ability of IFNg to increase levels of p21
, an important negative regulator of cell cycle events. IFNg was found to inhibit the growth of all cell lines, with inhibition ranging from 82.2% to 45.4%. Flow cytometry analysis showed that IFNg treatment caused a cell cycle delay in the G 1 or S phases. The strength of this delay varied, correlating with the degree by which IFNg inhibited proliferation of each cell line. IFNg treatment increased the production of the cyclin dependent kinase inhibitor (CKI) p21 WAF1/ CIP1 in all cell lines, the level and kinetics of production of which correlated with the degree and stage of inhibition of cellular proliferation. Further, immunoprecipitation of p21 WAF1/CIP1 in complexes of p21
/cyclin-dependent kinase 2 (cdk2)/cyclin showed that the amount of p21 WAF1/CIP1 in the complexes and the inhibition of cdk2-cyclin kinase activity correlated with the level of p21 WAF1/CIP1 produced in the cells by IFNg. These results show that IFNg has signi®cant antiproliferative eects on the glioblastoma cell lines and suggest that p21
Introduction
Glioblastoma multiforme is one of the most frequently occurring forms of brain cancer (Kleihues et al., 1995) . It typically aects adults between the ages of 45 and 60 years and is highly malignant. This form of glioma originates in astrocytic cells, which may undergo a number of mutations, the accumulation of which leads to the formation of glioblastoma. These tumors very frequently involve a mutation in the tumor suppressor gene p53 as well as ampli®cation of cyclin dependent kinase 4 (cdk) (Ohgaki et al., 1993) . Taken together these mutations can lead to uncontrolled cell cycling, which is the hallmark of all cancers. The tumor suppressor gene p53 plays an important role in protecting against tumor formation (Kastan et al., 1991; Greenblatt et al., 1994) . In response to DNA damage, p53 can induce the expression of the cyclindependent kinase inhibitor (CKI), p21 WAF1/CIP1 , which slows or stops the cell cycle in order to provide time to repair the damage and thus prevent replication errors.
The p21 WAF1/CIP1 protein is arguably one of the most important CKIs and its production is not solely dependent on p53 (Jiang et al., 1994; Parker et al., 1995) . It is a multifaceted protein capable of two main interactions that lead to the inhibition of cell growth (Xiong et al., 1993; Waga et al., 1994) . First, p21 WAF1/ CIP1 is able to bind and inhibit most cyclin-dependent kinase (cdk)-cyclin complexes. Second, p21 WAF1/CIP1 can inhibit replication by binding to the proliferating-cell nuclear antigen, PCNA, preventing it from activating DNA polymerase d. We have shown that type I interferons (IFN), which have antiproliferative eects on many cell types, are able to increase p21 WAF1/CIP1 production independent of p53 in prostate cancer cells and B cell plasmacytomas (Hobeika et al., 1997; Subramaniam and Johnson, 1997) . In this study we analyse the antiproliferative eects of the type II interferon, IFNg, on the glioblastoma cell lines T98G, SNB-19 and U-373, focusing on the ability of IFNg to increase levels of p21 WAF1/CIP1 . These studies show that IFNg treatment is eective in inhibiting the growth of all of these cell lines, leading to a delay in the G 1 or S phases of the cell cycle. Consistent with these ®ndings, IFNg treatment also leads to increased levels of p21 WAF1/CIP1 in all cell lines proportional to the inhibition of cellular proliferation.
Results and Discussion
We ®rst determined the antiproliferative eects of the type II IFN, IFNg, on the glioblastoma cell lines T98G, SNB-19, and U-373. These cells were treated with IFNg at concentrations ranging from 625 ± 10 000 units/ml and compared to media-treated cells for inhibition of growth as determined by direct cell counts. IFNg inhibited the growth of all cell lines in a dose dependent manner, with T98G and SNB-19 cells being most susceptible (Figure 1 ). Dose-response data indicated that 2500 units/ml of IFNg was the lowest concentration that achieved maximal inhibition, and this concentration was used in subsequent experiments. The cell lines were then treated with IFNg, and direct cell counts were obtained at dierent days of culture (Table 1) . As was found in the dose-response studies, IFNg was able to inhibit the growth of all cell lines to varying degrees, with the greatest eect on cell lines T98G (82.2% inhibition) and . The cell line U-373 was the least inhibited by IFNg at 45.4% inhibition. The percent viability of all of the IFNg treated cell lines was approximately 90%, suggesting that the mechanism of inhibition was not cytotoxicity or induced cell death. Thus, IFNg inhibited cell growth of several glioblastoma cell lines, but to varying degrees.
We next determined the eects of IFNg on the cell cycle of glioblastoma cell lines using¯ow cytometry in order to determine the cell cycle events aected by IFNg. Glioblastoma cells were synchronized into G 0 /G 1 by serum starvation in order to facilitate events at the various stages of the cell cycle. Cells were then stimulated to grow by addition of serum in the presence or absence of IFNg. T98G cells showed a very strong G 1 delay with 77.9% of IFNg treated cells still in the G 1 phase at 16 h versus 48.4% of untreated cells (Figure 2) . By 24 h, untreated cells had almost completed one full cycle while the IFNg treated cells were just entering the S phase (36.7%). This strong delay in the cell cycle correlated with the strong antiproliferative eect of IFNg seen on these cells in direct cell counts (Figure 1 ). U-373 cells showed a moderate G 1 delay, which correlated with the moderate antiproliferative eects of IFNg on this cell line ( Figure  3) . At 12 h, 79.2% of the IFNg treated cells were in the G 1 phase of the cell cycle compared to 72.1% of the untreated cells. This delay was then carried through a full cell cycle. SNB-19 cells showed a moderate G 1 delay at 20 h with 52.3% of the IFNg treated cells in the G 1 phase versus 40.8% of the untreated cells (Figure 4) . Unlike the predominant G 1 eects seen in the other cell lines, this delay became more pronounced in the S phase. This was seen at 32 h where the untreated cells had already completed one cell cycle versus the IFNg treated cells which were still in the S phase at 51.5%. This strong delay also correlated with the strong antiproliferative eect of IFNg on this cell line. Although the cell cycle progression of each cell Figure 2 IFNg inhibits the progression of T98G cells through the cell cycle causing a strong G 1 delay. T98G cells were synchronized in G 0 /G 1 by growing cells in media containing 0.5% FBS. Progress through the cell cycle was examined using propidium iodide staining followed by¯ow cytometry analysis. Horizontal axis: relative¯uorescence intensity. Vertical axis: number of cells line is delayed following IFNg treatment, the cells do continue to slowly progress through the cell cycle. We believe that this may be due to the positive growth signal contributed by the addition of complete media at the time of IFNg treatment, coupled with the fact that IFNg eectiveness may diminish over time. Since IFNg was not repeatedly added throughout the culture period the positive growth signal given by the addition of media may have eventually overcome the negative growth signal given by IFNg. It is also possible that these cell lines harbor a`leaky' mutation(s) which interferes in the mechanism of IFNg antiproliferative action. The degree of inhibition by IFNg did not appear to correlate with the cell cycling times. T98G, which has the fastest doubling time, was also the most sensitive to IFNg inhibition. However, the least sensitive cell line, U-373, had a similar doubling time to T98G. Thus, IFNg inhibited glioblastoma cell proliferation to varying degrees, and at dierent stages of the cell cycle.
To examine the mechanism involved in the antiproliferative eects of IFNg on these glioblastoma cell lines, we looked at the production of the CKI, p21
, in response to IFNg treatment. p21
is a tumor suppressor gene product which is a key and potent regulator of the cell cycle. It is known to form complexes with all cdk-cyclins and inhibit kinase activity that is required for cell cycling . It has been shown that STAT1a, a transcription factor that is activated upon treatment of cells with IFNg, binds to the promoter region of the p21 WAF1/CIP1 gene and induces transcription (Chin et al., 1996) . Synchronous cells from each cell line were treated with IFNg or media for 4 ± 16 h. Immunoblot analysis using p21 WAF1/CIP1 antibody on cell lysates showed increased p21 WAF1/CIP1 production in IFNg treated cells compared to untreated cells ( Figure 5 ). Cells that were more sensitive to IFNg antiproliferative activity showed greater increases in p21 WAF1/CIP1 production at 8 h in response to IFNg treatment relative to untreated cells ( Figure 6 ). T98G cells showed a 73-fold relative increase in p21 WAF1/CIP1 production when compared to control, which was the highest of all cell lines tested as measured by densitometric scanning. This result Figure 3 IFNg inhibits the progression of U-373 cells through the cell cycle causing a delay in the G 1 phase. U-373 cells were synchronized in G 0 /G 1 by growing cells in media containing 0.5% FBS. Progress through the cell cycle was examined using propidium iodide staining followed by¯ow cytometry analysis. Horizontal axis: relative¯uorescence intensity. Vertical axis: number of cells Figure 4 IFNg inhibits the progression of SNB-19 cells through the cell cycle causing a delay in the S phase. SNB-19 cells were synchronized in G 0 /G 1 by growing cells in media containing 0.5% FBS. Progress through the cell cycle was examined using propidium iodide staining followed by¯ow cytometry analysis. Horizontal axis: relative¯uorescence intensity. Vertical axis: number of cells IFNg increases levels of p21 WAF1/CIP1 in glioblastoma S. Kominsky et al correlated with the fact that T98G cells are also the most inhibited in the G 1 phase of the cell cycle by IFNg treatment (Figure 2 ). IFNg treated cells exhibited the most elevated p21 WAF1/CIP1 levels at 4 and 8 h compared to untreated cells. These results are consistent with the strong G 1 delay observed in T98G cells by¯ow cytometry. SNB-19 cells showed the second largest increase in p21 WAF1/CIP1 production in response to IFNg at 15.5-fold and were also the second most inhibited by IFNg treatment. U-373 cells showed a much lower increase in p21 WAF1/CIP1 production, 2.6-fold, compared to T98G and SNB-19 cells. This is consistent with the reduced sensitivity to IFNg induced growth inhibition and with the moderate early G 1 delay seen in this cell line. Thus, sensitivity to IFNg antiproliferative activity correlated with the increased levels of p21 WAF1/CIP1 following IFNg treatment in the cell lines, with the greatest increases in p21 WAF1/CIP1 production in those cell lines that were most inhibited by IFNg.
Asynchronous cells were next tested for the production of p21 WAF1/CIP1 in response to IFNg, since serum starvation itself causes some increased levels of p21 WAF1/CIP1 . Each cell line was treated with IFNg or media for 4 ± 16 h and p21 WAF1/CIP1 levels were assessed as decribed above. IFNg treated cells showed elevated levels of p21 WAF1/CIP1 compared to untreated cells (Figure 7) , indicating that IFNg treatment increases levels of p21 WAF1/CIP1 . It should be noted, however, that throughout this study synchronous cells were used to better follow cell cycle events.
To determine if p21 WAF1/CIP1 had a direct eect on the cell cycle we looked at the binding of p21 WAF1/CIP1 to cdk2, which is active in the G 1 and S phases of the cell cycle. T98G, SNB-19 and U-373 cells were synchronized by serum starvation and subsequently treated with IFNg for time periods ranging from 4 ± 8 h. Cell lysates were immunoprecipitated with anti-p21
antibodies and the presence of cdk2 was determined by immunoblotting ( Figure 8 ). In T98G cultures, p21 WAF1/ CIP1 -associated cdk2 levels were higher in IFNg treated cells than in untreated cells at 8 h, which is consistent with the growth inhibition by IFNg seen in these cultures. IFNg treated SNB-19 cells showed signi®cant levels of p21 WAF1/CIP1 -cdk2 complex as compared to untreated cells, although, these levels were lower than those found in T98G cells. The p21
-associated cdk2 levels in IFNg treated U-373 cells were relatively low compared to T98G and SNB-19 cells. Thus, the amount of p21 WAF1/CIP1 complexed to cdk2-cyclin for the cell lines correlated with the levels produced in response to IFNg treatment.
We next performed kinase assays to determine whether the increased binding of p21 WAF1/CIP1 to cdk2 Figure 5 IFNg treatment of synchronized cells (by serum starvation) increases p21 WAF1/CIP1 production in (a) T98G, (b) SNB-19 and (c) U-373 cells. Cells were grown for 24 h in serumfree media and subsequently incubated from 4 ± 16 h in complete media with or without 2500 units/ml IFNg. Immunoblot analysis was performed on cell lysates using p21 WAF1/CIP1 antibodies as described in Materials and methods. p21 WAF1/CIP1 levels in T98G and U-373 IFNg treated cells dropped to those seen in untreated cells at both 12 and 16 h (data not shown) Figure 6 The fold increase in p21 WAF1/CIP1 levels of IFNgtreated cells compared to untreated cells at 8 h was determined by densitometric scanning of radiographic ®lm for all cell lines Figure 7 IFNg treatment of asynchronous cells increases p21 WAF1/CIP1 production in (a) T98G, (b) SNB-19 and (c) U-373 cells. Cells were grown for 24 h in complete media and subsequently incubated from 4 ± 16 h with or without 2500 units/ ml IFNg. Immunoblot analysis was performed on cell lysates using p21 WAF1/CIP1 antibodies as described in Materials and methods. p21 WAF1/CIP1 levels in T98G and U-373 IFNg treated cells dropped to those seen in untreated cells at both 12 and 16 h (data not shown) . T98G cells showed the greatest reduction in cdk2 activity in response to IFNg, consistent with the fact that T98G cells were the most inhibited by IFNg and showed the strongest cell cycle delay following IFNg treatment. SNB-19 cells showed a reduction in cdk2 activity that increased at later time points. This is consistent with the pronounced S phase inhibition of the cell cycle. Cdk2 activity in U-373 cells was reduced following IFNg treatment, but to a lesser extent than was seen in the other two cell lines. This correlates with the moderate antiproliferative eects and cell cycle delay seen in this cell line following IFNg treatment. Taken together these results show that p21 WAF1/CIP1 produced in response to IFNg treatment binds cdk2 and reduces cdk2 activity proportionally to inhibition of cell growth.
To determine the ability of IFNg to increase the production of other CKIs we probed for the CKIs p16 and p27. IFNg treatment did not result in increased levels of p16 or p27 in any of the cell lines (data not shown). Thus, IFNg inhibitory eects do not involve p16 or p27.
IFNg has been shown to inhibit the growth of a number of cancer cell lines and aect various cell cycle players. In our studies on the eects of IFNg on the glioblastoma cell lines T98G, SNB-19 and U-373, we found that IFNg treatment inhibited the growth of all cell lines leading to a de®nitive delay in the G 1 to S phases of the cell cycle. Investigation into the eects of IFNg on cell cycle regulators showed that IFNg treatment increased the production of the CKI p21 WAF1/CIP1 in all cell lines. Furthermore, the fold increase in p21 WAF1/CIP1 levels induced by IFNg relative to controls appeared to coincide with both the degree to which each cell line was inhibited as well as the strength and location of the delay seen in the cell cycle of these cells. Thus increased levels of p21 WAF1/CIP1 produced in response to IFNg appeared to have a direct eect on the cell cycle in all cell lines. These results suggest that p21 WAF1/CIP1 may play an important role in mediating the eects of IFNg on these glioblastoma cell lines, although it is possible that other IFNg-associated activities contribute to these eects as well.
Although IFNg treatment led to delays in the cell cycle of all cell lines, the point at which the delays occurred varied. IFNg treatment of T98G and U-373 cells led to a distinctive G 1 delay, correlating with the kinetics of optimal production of p21 WAF1/CIP1 . SNB-19 cells showed only a slight G 1 delay in response to IFNg treatment, but did show a substantial S phase block. The absence of a signi®cant G 1 eect, but WAF1/CIP1 to cdk2 in (a) T98G, (b) SNB-19 and (c) U-373 cells. Cells were grown for 24 h in serum-free media and subsequently incubated over a time period ranging from 4 ± 8 h with or without 2500 units/ml IFNg. Cells lysates were immunoprecipitated using p21 WAF1/CIP1 antibodies and immunoblotted using cdk2 antibodies as described in Materials and methods. Results seen at 4 h (data not shown) were similar to those seen at 8 h (shown above)
IFNg increases levels of p21 WAF1/CIP1 in glioblastoma S. Kominsky et al presence of S phase block appears to correlate with the later kinetics of p21 WAF1/CIP1 production for this cell line. The CKIs p16 and p27 were not found to play a role in mediating the growth inhibitory eects of IFNg on the cell lines tested, although other cell cycle players may be involved. p21 WAF1/CIP1 is also able to inhibit replication by binding to PCNA and preventing it from activating DNA polymerase d . It has been shown that p21 WAF1/CIP1 binding to PCNA can lead to delays at both the G 1 and G 2 stages of the cell cycle (Cayrol et al., 1998) . IFNg is currently being used as an immunomodulatory molecule in the treatment of a number of cancers and is in clinical trials for use in many others. Our study shows that IFNg may be useful in the treatment of glioblastoma, and data suggests that IFNg directly aects the proliferation of glioblastoma cells and thus may be more eective if targeted directly to tumor tissue. However, testing IFNg in tissue culture seems to be a necessary and a more rational approach to therapeutic treatment of glioblastoma as we have shown that not all glioblastoma cell lines are aected to the same degree. Thus, in vitro screens of glioblastomas with IFNg may help determine candidates for targeted administration of IFNg in therapy.
Finally, in a separate study on the eects of a type I IFN, IFNa, on gliobalstoma cell lines (Tanabe et al., unpublished data), IFNa showed a dierent pattern of inhibition in cell lines T98G, SNB-19 and U-373 when compared to IFNg (Table 5) . It is of interest that the pattern of inhibition for IFNa correlated with increased production of p21 WAF1/CIP1 as was the case for IFNg. This provides additional evidence that IFN inhibition of glioblastomas positively correlates with relative levels of p21 WAF1/CIP1 . Thus IFN inhibition of glioblastoma growth, including the stage of cell cycle at which the antiproliferative eect is observed, correlates strongly with increased levels of p21 WAF1/CIP1
. 
Antiproliferation assay
T98G, U-373 and SNB-19 cells were plated at 1.0610 5 cells/well in six well plates. The cells were starved in media containing 0.5% FBS for 24 h. Cells were then treated with IFNg at a concentration of 2500 units/ml versus media alone and grown in media containing 5% FBS. The cells were trypsinized and removed from the plates at 48, 72 and 96 h time points. Cells were then counted using a hemocytometer and cell viability was determined by trypan blue dye (0.4%) exclusion.
Cell cycle analysis
T98G, U-373, and SNB-19 cells were seeded into 25 cm 2 asks (Sarstedt, Newton, NC, USA) and synchronized in G 0 /G 1 phase by culturing in starvation media for 24 (T98G) or 48 (U-373 and SNB-19) h. Cells were then treated with or without IFNg at 2500 units/ml and grown in media containing 10% FBS. At various time points cells were harvested and washed twice in sample buer (PBS containing 1% glucose). After centrifugation, cells were resuspended in 1 ml sample buer, centrifuged and ®xed by adding 1 ml cold ethanol (7208C) dropwise while gently vortexing. Samples were then stored at 48C for at least 24 h. Prior to analysis cells were washed twice with sample buer and resuspended in 600 ± 1000 ml sample buer containing 50 mg/ml propidium iodide and 50 units/ml RNase A (Sigma Co, St Louis, MO, USA). Samples were covered with foil and allowed to stain for up to 2 h at room temperature. Samples were then ®ltered through 44 mm nylon mesh and analysed using a FACSort (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) and the Lysis II software system. Cell cycle data was then analysed using CellFIT software.
Immunoprecipitation and immunoblotting
T98G, U-373 and SNB-19 cells were lysed at 48C for 20 min in 500 ml of cold lysis buer consisting of 50 mM Tris-HCl (pH 7.5), 0.25 M NaCl, 2 mM EDTA, 2 mM EGTA, 50 mM NaF, 20 mM b-glycerophosphate, 10% (vol/ vol) glycerol, 0.1% (vol/vol) Nonidet P-40, 2 mM Naorthovanadate, 2 mM dithiothreitol, leupeptin (10 mg/ml), pepstatin (10 mg/ml), aprotinin (10 mg/ml), benzamidine (5 mg/ml), and 1 mM phenylmethanesulfonyl¯uoride. Equal amounts of protein from cell lysates were immunoprecipitated with 1 mg of anti-p21 or anti-cdk2 antibody and resolved using 12% SDS ± PAGE (Biorad, Hercules, CA, USA). Protein was then transfered to ECL nitrocellulose membranes (Amersham). Following Western transfer, membranes were probed with anti-p21 or anticdk2 and developed using ECL (Amersham).
In vitro kinase assay
Immunoprecipitation of cdk2 was performed as described above. Following immunoprecipitation, samples were washed three times with lysis buer and twice with kinase buer (50 mM HEPES, pH 7.5, containing 1 mM EGTA, 10 mM MgCl 2 , 1 mM Na-orthovanadate, 2 mM DTT, 5 mM ATP, 20 mM b-glyceryl phosphate) and incubated in kinase buer containing 5 mg histone H1 and 20 mCi of [ 32 P]g-ATP (speci®c activity 6000 Ci/mmol; 1 mCi=37 Mbq) (Amersham) in a ®nal volume of 30 ml at 308C for 10 min. Samples were then centrifuged and analysed for histone H1 phosphorylation by a ®lter-binding assay using centrifugal Pierce phosphocellulose units, SpinZyme TM Format purchased from Pierce (Rockford, IL) according to the manufacturer's instructions.
